Androgen Receptor Inhibitor [EPC]

73909 reported adverse events

Drugs of this class: BICALUTAMIDE FLUTAMIDE CLASCOTERONE ENZALUTAMIDE NILUTAMIDE

These side effects are most commonly reported by patients taking drugs of the Androgen Receptor Inhibitor [EPC] class:

# Side effect Count
0 FATIGUE 11173
1 DEATH 8581
2 MALIGNANT NEOPLASM PROGRESSION 5912
3 PROSTATIC SPECIFIC ANTIGEN INCREASED 4949
4 ASTHENIA 4785
5 DRUG INEFFECTIVE 4629
6 HOT FLUSH 4486
7 DECREASED APPETITE 3749
8 NAUSEA 3681
9 DIZZINESS 3611
See all common reactions for Androgen Receptor Inhibitor [EPC]

Drugs of the Androgen Receptor Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PROSTATIC SPECIFIC ANTIGEN INCREASED 4949 0.3589
1 PROSTATIC SPECIFIC ANTIGEN ABNORMAL 249 0.2399
2 HORMONE-REFRACTORY PROSTATE CANCER 248 0.2088
3 PROSTATE CANCER METASTATIC 561 0.1678
4 PRODUCT SIZE ISSUE 616 0.1145
5 PRODUCT PHYSICAL CONSISTENCY ISSUE 351 0.0634
6 BLOOD TESTOSTERONE INCREASED 132 0.0613
7 HOT FLUSH 4486 0.0595
8 MALIGNANT NEOPLASM PROGRESSION 5912 0.0577
9 METASTASES TO BONE 898 0.0547
See all enriched reactions for Androgen Receptor Inhibitor [EPC]